dm+d

Unassigned

New Medicines

Follicular lymphoma or marginal zone lymphoma, relapsed or refractory, as monotherapy or in combination with rituximab - third-line or greater

Information

New molecular entity
Not Known
MEI Pharma

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Selective phosphatidylinositol 3-kinase (PI3K) delta inhibitor [1]
Follicular lymphoma is a type of Non-Hodgkin lymphoma that is low grade (about 20-25% of NHLs). The annual incidence of follicular lymphomas has increased from 2-3 per 100,000 during the 1950s to 5-7 per 100,000 recently. The vast majority of relapses occur in the first two years after therapy.
Follicular lymphoma or marginal zone lymphoma, relapsed or refractory, as monotherapy or in combination with rituximab - third-line or greater
Oral